Sónia Melo Gomes
Sónia is an honorary Clinical Research Fellow at GOSH, having finished her PhD in genetics of autoinflammation at the UCL GOSH Institute of Child Health in London, UK. She is also a member of the executive committee of EMERGE, with responsibilities in the organisation of the Young Investigators Meeting, as well as being the lead of the EMEUNET Global Affairs and Country Liaison Subcommittee.
| Poster 0157 | Thursday 13.06.2024 12:30 PM Paediatric Poster Tours: Novel developments in paediatric rheumatology Author: Bustaffa, M (Italy) Title: The Eurofever FMF Longitudinal Cohort: First Longitudinal Data  Longitudinal data from the FMF cohort of the Eurofever registry showing ±50% complete remission after a mean follow-up of 5.4 years. |
| Oral 0211 | Friday 14.06.2024 10:30 AM Paediatric Abstract Sessions: Paediatric Rheumatology Presentations Author: Horneff, G (Germany) Title: Treat-to-target In Polyarticular Juvenile Idiopathic Arthritis – A Protocols In Paediatric Rheumatology (Prokind) Study This prospective observational study of polyarticular JIA patients showed 2/3 reached inactive disease during the first year of treatment, following a treat-to-target approach. |
| Oral 0226 | Friday 14.06.2024 10:40 AM Paediatric Abstract Sessions: Paediatric Rheumatology Presentations Author: Bootsma, H (Netherlands) Title: Potential Value of The Blood Interferon Signature in the Diagnosis of Pediatric-onset Sjögren’s Disease Patients This study showed a raised interferon (IFN) signature in blood and parotid gland tissue in 72% of patients of a cohort of patients with paediatric Sjögren’s disease, suggesting that an IFN signature may aid in the diagnosis and stratification of these patients. |
| Oral 0246 | Friday 14.06.2024 10:50 AM Paediatric Abstract Sessions: Paediatric Rheumatology Presentations Author: Hanif, M (UK) Title: Factors Associated with Damage Accrual in Childhood Systemic Lupus Erythematosus (cSLE): Corticosteroid Regimens And Maintenance Of Low Disease Activity This analysis of the UK childhood SLE cohort identified methylprednisolone exposure as a significant and potentially modifiable risk factor for damage in cSLE, warranting a review of paediatric dose limits. |
| Oral 0277 | Friday 14.06.2024 11:10 AM Paediatric Abstract Sessions: Paediatric Rheumatology Presentations Author: Sarker, C (UK) Title: Evaluating the Impact of Childhood-onset Systemic Lupus Erythematosus T2T Target Attainment: Mitigating Flares and New Damage Accrual This longitudinal study validated the new cSLE treat-to-target endpoints, comparing them to the adult equivalents. The data showed that achieving cLLDAS, cCR and cCR-0 led to reductions in the risk of severe flare and new damage. |
| Poster 0304 | Friday 14.06.2024 12:18 PM Basic Poster Tours: Impact of therapy on lupus immunity Author: Natoli, V (UK) Title: Allele Counts Associate With Early Disease Onset, Organ Involvement And Disease Severity In Juvenile-onset Systemic Lupus Erythematosus This study used a panel sequencing approach to demonstrate that genetic variability contributed to early disease expression, especially in Black African/Caribbean and South-Asian jSLE patients, and was associated with organ involvement and severity overall. |
| Oral LBA009 | Saturday 15.06.2024 09:20 AM Oral Abstract Sessions: Late breaking abstracts 2 Author: Ramanan, AV (UK) Title: Efficacy and Safety of Ixekizumab in Children with Active Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis (Cospirit-jia): 16-week Results of a Multicentre, Randomised, Open-label Study This study of the efficacy of ixekizumab in paediatric patients with juvenile PsA and ERA showed an 88.9% JIA ACR30 response rate at week 16. |